BACKGROUND
Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional sta...
G. C. Giudice, Hassan M. Abushukair, G. Mazzaschi et al.· The Oncologist· 0 citations
Despite many treatment strategies available for metastatic renal cell carcinoma (mRCC), predictive biomarkers of response to immunotherapy are still needed. In this context, growing efforts have been devoted to translational research, especially focusing on the immune tumor microenvironment (I-TME).
The Me...
S. E. Rebuzzi, F. Catalano, Francesca Schiavi et al.· Cancer Immunology and Immuno...· 0 citations
Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· Cancer Metastasis Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.